Published in Hypertension on October 17, 2005
Elevated maternal C-reactive protein and increased risk of schizophrenia in a national birth cohort. Am J Psychiatry (2014) 2.91
Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation (2011) 2.55
Mechanisms of implantation: strategies for successful pregnancy. Nat Med (2012) 2.50
The effect of immune factors, tumor necrosis factor-alpha, and agonistic autoantibodies to the angiotensin II type I receptor on soluble fms-like tyrosine-1 and soluble endoglin production in response to hypertension during pregnancy. Am J Hypertens (2010) 2.23
Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med (2006) 2.16
Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalischemia-induced hypertension. Hypertension (2009) 1.82
Recent progress toward the understanding of the pathophysiology of hypertension during preeclampsia. Hypertension (2008) 1.72
Recent advances in the understanding of the pathophysiology of preeclampsia. Hypertension (2013) 1.71
Autoantibodies to the angiotensin type I receptor in response to placental ischemia and tumor necrosis factor alpha in pregnant rats. Hypertension (2008) 1.65
Interferon-α and angiogenic dysregulation in pregnant lupus patients who develop preeclampsia. Arthritis Rheumatol (2015) 1.61
Role of endothelin in mediating soluble fms-like tyrosine kinase 1-induced hypertension in pregnant rats. Hypertension (2009) 1.49
Hypertension produced by placental ischemia in pregnant rats is associated with increased soluble endoglin expression. Hypertension (2008) 1.45
Oxidative stress contributes to soluble fms-like tyrosine kinase-1 induced vascular dysfunction in pregnant rats. Am J Hypertens (2009) 1.41
Elevated maternal C-reactive protein and autism in a national birth cohort. Mol Psychiatry (2013) 1.38
C5a enhances dysregulated inflammatory and angiogenic responses to malaria in vitro: potential implications for placental malaria. PLoS One (2009) 1.16
Inhibition of VEGF or TGF-{beta} signaling activates endothelium and increases leukocyte rolling. Arterioscler Thromb Vasc Biol (2009) 1.14
Recent insights into the pathophysiology of preeclampsia. Expert Rev Obstet Gynecol (2010) 1.14
Dysregulated complement activation as a common pathway of injury in preeclampsia and other pregnancy complications. Placenta (2010) 1.08
Vascular endothelial cell growth factor-a: not just for endothelial cells anymore. Am J Pathol (2007) 1.07
Maternal plasma concentrations of angiogenic/antiangiogenic factors in the third trimester of pregnancy to identify the patient at risk for stillbirth at or near term and severe late preeclampsia. Am J Obstet Gynecol (2013) 1.05
Regulation of sFlt-1 and VEGF secretion by adenosine under hypoxic conditions in rat placental villous explants. Am J Physiol Regul Integr Comp Physiol (2010) 1.00
Angiogenic factors in preeclampsia and related disorders. Cold Spring Harb Perspect Med (2012) 0.99
Upregulation of long noncoding RNA SPRY4-IT1 modulates proliferation, migration, apoptosis, and network formation in trophoblast cells HTR-8SV/neo. PLoS One (2013) 0.97
Exercise training attenuates placental ischemia-induced hypertension and angiogenic imbalance in the rat. Hypertension (2012) 0.96
Control of soluble fms-like tyrosine-1 (sFlt-1) production response to placental ischemia/hypoxia: role of tumor necrosis factor-α. Am J Physiol Regul Integr Comp Physiol (2012) 0.95
Placental ischemia and cardiovascular dysfunction in preeclampsia and beyond: making the connections. Expert Rev Cardiovasc Ther (2008) 0.94
L-arginine supplementation abolishes the blood pressure and endothelin response to chronic increases in plasma sFlt-1 in pregnant rats. Am J Physiol Regul Integr Comp Physiol (2011) 0.93
Preeclampsia and small-for-gestational age are associated with decreased concentrations of a factor involved in angiogenesis: soluble Tie-2. J Matern Fetal Neonatal Med (2008) 0.92
Pathogenic role of antiphospholipid antibodies. Lupus (2008) 0.89
The novel inflammatory cytokine high mobility group box protein 1 (HMGB1) is expressed by human term placenta. Immunology (2007) 0.89
Circulating angiogenic and antiangiogenic factors in women with eclampsia. Am J Obstet Gynecol (2010) 0.88
Agonistic autoantibodies to the angiotensin II type I receptor cause pathophysiologic characteristics of preeclampsia. Gend Med (2012) 0.87
Role of reactive oxygen species during hypertension in response to chronic antiangiogenic factor (sFlt-1) excess in pregnant rats. Am J Hypertens (2010) 0.86
Tissue factor and its natural inhibitor in pre-eclampsia and SGA. J Matern Fetal Neonatal Med (2008) 0.86
Carbon monoxide prevents hypertension and proteinuria in an adenovirus sFlt-1 preeclampsia-like mouse model. PLoS One (2014) 0.86
Matrix metalloproteinases as drug targets in preeclampsia. Curr Drug Targets (2013) 0.85
Nitric oxide and reactive oxygen species in the pathogenesis of preeclampsia. Int J Mol Sci (2015) 0.85
Over-expression of the thrombin receptor (PAR-1) in the placenta in preeclampsia: a mechanism for the intersection of coagulation and inflammation. J Matern Fetal Neonatal Med (2008) 0.84
Biomarkers for the management of pre-eclampsia in pregnant women. Indian J Med Res (2013) 0.84
Altered matrix metalloproteinase-2 and -9 expression/activity links placental ischemia and anti-angiogenic sFlt-1 to uteroplacental and vascular remodeling and collagen deposition in hypertensive pregnancy. Biochem Pharmacol (2014) 0.83
An Elevated Maternal Plasma Soluble fms-Like Tyrosine Kinase-1 to Placental Growth Factor Ratio at Midtrimester Is a Useful Predictor for Preeclampsia. Obstet Gynecol Int (2013) 0.83
Levels of soluble fms-like tyrosine kinase one in first trimester and outcomes of pregnancy: a systematic review. Reprod Biol Endocrinol (2011) 0.83
Differential expression of Vegfr-2 and its soluble form in preeclampsia. PLoS One (2012) 0.82
Effects of angiogenic factors, antagonists, and podocyte injury on development of proteinuria in preeclampsia. Reprod Sci (2012) 0.81
Pathogenesis and promising non-invasive markers for preeclampsia. Obstet Gynecol Sci (2013) 0.80
In vivo experiments reveal the good, the bad and the ugly faces of sFlt-1 in pregnancy. PLoS One (2014) 0.80
Angiogenic dysfunction in molar pregnancy. Am J Obstet Gynecol (2010) 0.80
The imbalance in expression of angiogenic and anti-angiogenic factors as candidate predictive biomarker in preeclampsia. Iran J Reprod Med (2015) 0.79
Maternal plasma soluble TRAIL is decreased in preeclampsia. J Matern Fetal Neonatal Med (2013) 0.79
The endoplasmic reticulum stress of placental impoverishment. Am J Pathol (2008) 0.79
Placental Growth Factor Administration Abolishes Placental Ischemia-Induced Hypertension. Hypertension (2016) 0.79
MiR-101 regulates apoptosis of trophoblast HTR-8/SVneo cells by targeting endoplasmic reticulum (ER) protein 44 during preeclampsia. J Hum Hypertens (2014) 0.79
Full-length human placental sFlt-1-e15a isoform induces distinct maternal phenotypes of preeclampsia in mice. PLoS One (2015) 0.78
Molecular Mechanisms of Preeclampsia. Cold Spring Harb Perspect Med (2015) 0.78
Progesterone supplementation attenuates hypertension and the autoantibody to the angiotensin II type I receptor in response to elevated interleukin-6 during pregnancy. Am J Obstet Gynecol (2014) 0.77
Prenatal stretching exercise and autonomic responses: preliminary data and a model for reducing preeclampsia. J Nurs Scholarsh (2010) 0.76
Is there any difference between preeclamptic and healthy pregnant women regarding the presence of periopathogenic bacteria in the placenta? Int J Prev Med (2013) 0.76
Transthyretin regulates the migration and invasion of JEG-3 cells. Oncol Lett (2016) 0.75
Difference of concentration of placental soluble fms-like tyrosine kinase-1(sFlt-1), placental growth factor (PlGF), and sFlt-1/PlGF ratio in severe preeclampsia and normal pregnancy. BMC Res Notes (2015) 0.75
Correlation between cell-free mRNA expressions and PLGF protein level in severe preeclampsia. BMC Res Notes (2015) 0.75
Circulating Vascular Growth Factor (VEGF) Angiopoietin-1 (Angi-1) and Soluble Tie-2 Receptor in Pregnancy Complicated with Pre-eclampsia: A Prospective Study. J Obstet Gynaecol India (2013) 0.75
Decorin-Mediated Inhibition of Human Trophoblast Cells Proliferation, Migration, and Invasion and Promotion of Apoptosis In Vitro. Biomed Res Int (2015) 0.75
Immune activation during the implantation phase causes preeclampsia-like symptoms via the CD40-CD40 ligand pathway in pregnant mice. Hypertens Res (2016) 0.75
The effect of Silymarin on VEGF, VEGFR-1 and IL-1α levels in placental cultures of severe preeclamptic women. J Turk Ger Gynecol Assoc (2014) 0.75
Regulation of soluble fms-like tyrosine kinase-1 production in response to placental ischemia/hypoxia: role of angiotensin II. Physiol Rep (2015) 0.75
Progress in obstetrics or the road to the promised land. J Med Life (2010) 0.75
Sildenafil citrate for the management of fetal growth restriction and oligohydramnios. Int J Womens Health (2016) 0.75
Decreased Homodimerization and Increased TIMP-1 Complexation of Uteroplacental and Uterine Arterial Matrix Metalloproteinase-9 during Hypertension-in-Pregnancy. Biochem Pharmacol (2017) 0.75
Increased Vascular and Uteroplacental Matrix Metalloproteinase-1 and -7 Levels and Collagen I Deposition in Hypertension-in-Pregnancy. Role of TNF. Am J Physiol Heart Circ Physiol (2017) 0.75
Matrix Metalloproteinases in Normal Pregnancy and Preeclampsia. Prog Mol Biol Transl Sci (2017) 0.75
The Comparison of the T2-star Values of Placentas Obtained from Preeclamptic Patients with Those of a Control Group: an Ex-vivo Magnetic Resonance Imaging Study. Balkan Med J (2017) 0.75
Resolution of inflammation pathways in preeclampsia-a narrative review. Immunol Res (2017) 0.75
Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med (2004) 14.00
Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest (2003) 13.72
Vitamin D-binding protein and vitamin D status of black Americans and white Americans. N Engl J Med (2013) 9.87
Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med (2006) 7.06
Circulating urokinase receptor as a cause of focal segmental glomerulosclerosis. Nat Med (2011) 6.35
Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat Med (2006) 6.21
Excess circulating angiopoietin-2 may contribute to pulmonary vascular leak in sepsis in humans. PLoS Med (2006) 3.72
A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med (2008) 3.39
Pilot study of extracorporeal removal of soluble fms-like tyrosine kinase 1 in preeclampsia. Circulation (2011) 3.33
Sequential changes in antiangiogenic factors in early pregnancy and risk of developing preeclampsia. Hypertension (2007) 2.77
Urinary placental growth factor and risk of preeclampsia. JAMA (2005) 2.76
Vascular endothelial growth factor is an important determinant of sepsis morbidity and mortality. J Exp Med (2006) 2.75
Bioavailable vitamin D is more tightly linked to mineral metabolism than total vitamin D in incident hemodialysis patients. Kidney Int (2012) 2.74
Vascular endothelial growth factor-A and aldosterone: relevance to normal pregnancy and preeclampsia. Hypertension (2013) 2.70
Pathogenesis of preeclampsia. Annu Rev Pathol (2010) 2.66
Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension (2007) 2.62
Confocal light absorption and scattering spectroscopic microscopy monitors organelles in live cells with no exogenous labels. Proc Natl Acad Sci U S A (2007) 2.56
Vitamin D-binding protein modifies the vitamin D-bone mineral density relationship. J Bone Miner Res (2011) 2.55
Preeclampsia, a disease of the maternal endothelium: the role of antiangiogenic factors and implications for later cardiovascular disease. Circulation (2011) 2.55
Angiopoietin-2 may contribute to multiple organ dysfunction and death in sepsis*. Crit Care Med (2012) 2.32
Vitamin D deficiency and cardiovascular events in patients with coronary heart disease: data from the Heart and Soul Study. Am J Epidemiol (2014) 2.30
Cardiac angiogenic imbalance leads to peripartum cardiomyopathy. Nature (2012) 2.27
Activated vitamin D attenuates left ventricular abnormalities induced by dietary sodium in Dahl salt-sensitive animals. Proc Natl Acad Sci U S A (2007) 2.25
Clinical characterization and outcomes of preeclampsia with normal angiogenic profile. Hypertens Pregnancy (2013) 2.22
Early outcomes among those initiating chronic dialysis in the United States. Clin J Am Soc Nephrol (2011) 2.17
First trimester placental growth factor and soluble fms-like tyrosine kinase 1 and risk for preeclampsia. J Clin Endocrinol Metab (2004) 2.11
Preeclampsia: the role of angiogenic factors in its pathogenesis. Physiology (Bethesda) (2009) 2.10
Angiopoietin 2 is a partial agonist/antagonist of Tie2 signaling in the endothelium. Mol Cell Biol (2009) 2.09
Preeclampsia and angiogenic imbalance. Annu Rev Med (2008) 2.05
Circulating levels of the antiangiogenic marker sFLT-1 are increased in first versus second pregnancies. Am J Obstet Gynecol (2005) 2.03
Endothelial dysfunction: a link among preeclampsia, recurrent pregnancy loss, and future cardiovascular events? Hypertension (2006) 2.02
Molecular mechanisms of preeclampsia. Microvasc Res (2007) 1.90
PGC-1α promotes recovery after acute kidney injury during systemic inflammation in mice. J Clin Invest (2011) 1.88
Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation (2012) 1.88
Transcriptionally active syncytial aggregates in the maternal circulation may contribute to circulating soluble fms-like tyrosine kinase 1 in preeclampsia. Hypertension (2012) 1.86
Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalischemia-induced hypertension. Hypertension (2009) 1.82
Diagnostic utility of soluble fms-like tyrosine kinase 1 and soluble endoglin in hypertensive diseases of pregnancy. Am J Obstet Gynecol (2007) 1.80
Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia. Pediatr Res (2005) 1.78
Uric acid, endothelial dysfunction and pre-eclampsia: searching for a pathogenetic link. J Hypertens (2004) 1.71
Pathophysiology of the clinical manifestations of preeclampsia. Clin J Am Soc Nephrol (2007) 1.69
Pre-eclampsia: clinical manifestations and molecular mechanisms. Nephron Clin Pract (2007) 1.67
Cytomegalovirus-induced mirror syndrome associated with elevated levels of circulating antiangiogenic factors. Obstet Gynecol (2007) 1.67
Interferon-α and angiogenic dysregulation in pregnant lupus patients who develop preeclampsia. Arthritis Rheumatol (2015) 1.61
Pre-eclampsia, soluble fms-like tyrosine kinase 1, and the risk of reduced thyroid function: nested case-control and population based study. BMJ (2009) 1.59
Angiogenic factors and preeclampsia. Semin Nephrol (2011) 1.58
VEGF and TGF-beta are required for the maintenance of the choroid plexus and ependyma. J Exp Med (2008) 1.54
Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. J Biol Chem (2002) 1.51
The glomerular injury of preeclampsia. J Am Soc Nephrol (2007) 1.50
Protease activity of urokinase and tumor progression in a syngeneic mammary cancer model. J Natl Cancer Inst (2006) 1.49
Familial factors in the association between preeclampsia and later ESRD. Clin J Am Soc Nephrol (2012) 1.47
Hypothesis: Uric acid, nephron number, and the pathogenesis of essential hypertension. Kidney Int (2004) 1.42
First trimester vitamin D, vitamin D binding protein, and subsequent preeclampsia. Hypertension (2010) 1.39
Lipocalin 2 diminishes invasiveness and metastasis of Ras-transformed cells. J Biol Chem (2005) 1.36
Endostatin is a potential inhibitor of Wnt signaling. J Cell Biol (2002) 1.34
Preeclampsia and future cardiovascular disease: potential role of altered angiogenesis and insulin resistance. J Clin Endocrinol Metab (2004) 1.34
Longitudinal evaluation of predictive value for preeclampsia of circulating angiogenic factors through pregnancy. Am J Obstet Gynecol (2012) 1.33
Hypoxia and sFlt-1 in preeclampsia: the "chicken-and-egg" question. Endocrinology (2004) 1.33
Prediction of diabetic nephropathy using urine proteomic profiling 10 years prior to development of nephropathy. Diabetes Care (2007) 1.32
Vascular endothelial growth factor induces branching morphogenesis/tubulogenesis in renal epithelial cells in a neuropilin-dependent fashion. Mol Cell Biol (2005) 1.29
Serum sFlt1 concentration during preeclampsia and mid trimester blood pressure in healthy nulliparous women. Am J Obstet Gynecol (2006) 1.28
Activation of the orphan endothelial receptor Tie1 modifies Tie2-mediated intracellular signaling and cell survival. FASEB J (2007) 1.27
Effects of a synthetic PEG-ylated Tie-2 agonist peptide on endotoxemic lung injury and mortality. Am J Physiol Lung Cell Mol Physiol (2011) 1.25
Carbamylation of serum albumin as a risk factor for mortality in patients with kidney failure. Sci Transl Med (2013) 1.25
Mapping the theories of preeclampsia and the role of angiogenic factors: a systematic review. Obstet Gynecol (2007) 1.20
Breathing life into the lifecourse approach: pregnancy history and cardiovascular disease in women. Hypertension (2010) 1.20
The CXCR4/CXCR7/SDF-1 pathway contributes to the pathogenesis of Shiga toxin-associated hemolytic uremic syndrome in humans and mice. J Clin Invest (2012) 1.18
Increased sensitivity to angiotensin II is present postpartum in women with a history of hypertensive pregnancy. Hypertension (2010) 1.18
New aspects in the pathophysiology of preeclampsia. J Am Soc Nephrol (2004) 1.17
Twin pregnancy and the risk of preeclampsia: bigger placenta or relative ischemia? Am J Obstet Gynecol (2008) 1.17
Plasma gelsolin and circulating actin correlate with hemodialysis mortality. J Am Soc Nephrol (2009) 1.16
Circulating angiogenic factors and placental abruption. Obstet Gynecol (2006) 1.15
Circulating angiogenic factors in preeclampsia. Clin Obstet Gynecol (2005) 1.12
Reduced endoglin activity limits cardiac fibrosis and improves survival in heart failure. Circulation (2012) 1.12
Hypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarker. Semin Nephrol (2010) 1.11
Abnormal placentation, angiogenic factors, and the pathogenesis of preeclampsia. Obstet Gynecol Clin North Am (2010) 1.11
Angiogenic factors in diagnosis, management, and research in preeclampsia. Hypertension (2013) 1.11
WT1-dependent sulfatase expression maintains the normal glomerular filtration barrier. J Am Soc Nephrol (2011) 1.10
Pre-eclampsia and cardiovascular disease. Cardiovasc Res (2014) 1.10
Vitamin D-binding protein and vitamin D in blacks and whites. N Engl J Med (2014) 1.08
Conversion of peripheral blood NK cells to a decidual NK-like phenotype by a cocktail of defined factors. J Immunol (2013) 1.07
Expectant management of uterine dehiscence in the second trimester of pregnancy. Obstet Gynecol (2003) 1.07
Suppression of the nitric oxide pathway in metastatic renal cell carcinoma patients receiving vascular endothelial growth factor-signaling inhibitors. Hypertension (2010) 1.05
Soluble Fms-like tyrosine kinase associated with preeclampsia in pregnancy in systemic lupus erythematosus. J Rheumatol (2008) 1.05
eNOS deficiency acts through endothelin to aggravate sFlt-1-induced pre-eclampsia-like phenotype. J Am Soc Nephrol (2012) 1.05
Cisplatin nephrotoxicity involves mitochondrial injury with impaired tubular mitochondrial enzyme activity. J Histochem Cytochem (2012) 1.05
Aldosterone promotes vascular remodeling by direct effects on smooth muscle cell mineralocorticoid receptors. Arterioscler Thromb Vasc Biol (2013) 1.04
Preventing progression of cardiac hypertrophy and development of heart failure by paricalcitol therapy in rats. Cardiovasc Res (2011) 1.04
Automated assays for sVEGF R1 and PlGF as an aid in the diagnosis of preterm preeclampsia: a prospective clinical study. Am J Obstet Gynecol (2009) 1.03
The use of angiogenic biomarkers to differentiate non-HELLP related thrombocytopenia from HELLP syndrome. J Matern Fetal Neonatal Med (2010) 1.03
Hydrogen sulfide attenuates sFlt1-induced hypertension and renal damage by upregulating vascular endothelial growth factor. J Am Soc Nephrol (2013) 1.03
Excess soluble vascular endothelial growth factor receptor-1 in amniotic fluid impairs lung growth in rats: linking preeclampsia with bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol (2011) 1.03